Showing results (61-70 of 75) with videos related to
Sort By:
Pageof 8
Journal of Cardiovascular Electrophysiology|January 28, 2017
Association of Antitachycardia Pacing or Shocks With Survival in 69,000 Patients With an Implantable DefibrillatorS Adam Strickberger, Robert Canby, Joshua Cooper, et al.Journal of the Endocrine Society|December 19, 2022
Case-control Investigation of Previously Undiagnosed Diabetes in the Critically IllJames S Krinsley, Gregory Roberts, Michael Brownlee, et al.Journal of Diabetes Science and Technology|August 16, 2021
Acute and Chronic Glucose Control in Critically Ill Patients With Diabetes: The Impact of Prior Insulin TreatmentJames S Krinsley, Peter Rule, Michael Brownlee, et al.American Journal of Speech-Language Pathology|October 19, 2023
Evaluating the Efficacy of a Narrative Language Intervention for Bilingual StudentsPhilip Capin, Sharon Vaughn, Sandra Laing Gillam, et al.JAMA Cardiology|July 21, 2016
Time Course of Subsequent Shocks After Initial Implantable Cardioverter-Defibrillator Discharge and Implications for Driving RestrictionsFaisal M Merchant, Michael H Hoskins, Michael E Benser, et al.Targeted Oncology|March 6, 2014
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trialBrian I Rini, David I Quinn, Michael Baum, et al.JAMA Cardiology|May 16, 2019
Association of Ambulatory Hemodynamic Monitoring of Heart Failure With Clinical Outcomes in a Concurrent Matched Cohort AnalysisJacob Abraham, Rupinder Bharmi, Orvar Jonsson, et al.The Journal of Biological Chemistry|March 31, 2007
Cellular characterization of a novel focal adhesion kinase inhibitorJill K Slack-Davis, Karen H Martin, Robert W Tilghman, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 29, 2012
Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumorsJeffrey R Infante, D Ross Camidge, Linda R Mileshkin, et al.Investigational New Drugs|September 4, 2015
A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumorsSuzanne F Jones, Lillian L Siu, Johanna C Bendell, et al.Pageof 8